Exosome Diagnostic And Therapeutic Market Size, Share & Trends
The global exosome diagnostic and therapeutic market size was valued at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosome is the membrane-bound vesicle that is synthesized in the extracellular compartment of the eukaryotic cells. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Biomolecules, including proteins, metabolites, and nucleic acids are delivered by exosomes into target cells effectively to alter their biological response. Exosomes are engineered to deliver diverse therapeutic payloads, including short interfering ribonucleic acid (RNAs), antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. Exosome vesicle-based liquid biopsy is used for potential utilization in diagnosis and determining the prognosis of patients with cancer and other disease.
The exosome diagnostic and therapeutic market share is primarily driven by increase in prevalence of chronic disease, infectious disease, autoimmune disease and cancer and surge in demand for molecular diagnosis. In addition, ongoing advance exosome technology in drug development and discovery yields valuable information regarding the heterogeneity and biological function and enhances the ability to harness the therapeutic and diagnostic potential for cancer & infectious disease. Thus, advancement in technology in healthcare sector propels the growth of the exosome diagnostic market, and exosome therapeutic market.
Increase in demand for drug therapies and surge in R&D activities in pharmaceutical and biopharmaceutical field which is stimulated by the potential of exosome technologies as diagnostic and therapeutic tools are used for the treatment of various diseases, including neurodegeneration, cardiovascular dysfunction, and cancer. Increase in potential application of exosome in cancer diagnosis and development of translational precision medicine increase the use of exosome diagnostic and therapeutic industry and surge the growth of exosome diagnostic market, and exosome therapeutic market.
The key factor for the exosome diagnostic and therapeutic market growth includes increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer disease , Parkinson’s disease , and cancer, including breast, prostate, liver, and lung cancer which , in turn, boosts to growth of the market . Furthermore, on August 2020, Aethlon Medical, a healthcare company, announced the collaboration with University of Pittsburgh on National Institute of Health Grant for treatment of head and neck cancer. Exosomes are nanosized particles that are released in large quantities from cancer cells and carry complement of a tumor's genetic and protein cargo, which fuel cancer growth and immune suppression.
In addition, in April 2020, Exosome Diagnostics, a biotechnology company, announced the launch of ExoDx Prostate test kit at-home. ExoDx Prostate (EPI) test is a urine-based, genomic test that helps to detect prostate cancer . This liquid biopsy test recently received coverage in the VA Healthcare system through a General Services Administration (GSA) award and is included in the National Cancer Comprehensive Network (NCCN) guidelines for early detection in men .
Exosomes Diagnostic And Therapeutic Market Segmentation
The exosome diagnostic and therapeutic market is segmented into application, product, end user and region. Depending on the application, it is divided into diagnostic and therapeutic applications. By the product, it is fragmented into instrument, reagents, and software. According to end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations).
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
By application, the diagnostic segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for early diagnosis. However, the therapeutics segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for drug development.
By Application
Diagnostic segment would witness the fastest growth, registering a CAGR of 28.8% during the forecast period.
Depending on product, the reagents segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. However, the instrument segment is expected to witness considerable growth during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in number of key manufacturer.
By Product
Software segment Enterprises segment was the highest revenue contributor during the forecast period.
According to end user, the cancer institute segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of cancer, increase in number of hospitals and surge in initiatives by government for development of healthcare infrastructure. However, the diagnostic center segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for molecular diagnosis.
By End User
Cancer Institute segment held the major share of 29.7% throughout the forecast period.
Region wise, North America garnered a major share in the exosome diagnostic and therapeutic market in 2020, and is expected to be dominant during the exosome diagnostic and therapeutic market forecast period, owing to rise in prevalence of chronic disorder, increase in number of product launch for exosome therapeutics, surge in presence of key players, and development of R&D activities in pharmaceutical and biopharmaceutical sector in the region. However, Asia-Pacific is expected to register highest CAGR of 30.3% from 2021 to 2030, owing to increase in prevalence of chronic and infectious disorder, growth in health care expenditures, rise in number of exosome diagnostic and therapeutic industry and surge in demand for molecular diagnosis.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Competition Analysis
The key players operating in the global exosome diagnostic and therapeutic market include Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark). The other players in the value chain include 101BIO, AMS Biotechnology Limited, Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, ExoCyte Therapeutics Pte Ltd., Cell Guidance Systems LLC, BioRegenerative Sciences, Inc., Evomic Science LLC, and Norgen Biotek Corp.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies
Exosome Diagnostic and Therapeutic Market Report Highlights
| Aspects | Details |
 Market Size By 2030 | USD 2.9 billion |
 Growth Rate | CAGR of 29.4% |
 Forecast period | 2020 - 2030 |
 Report Pages | 110 |
 By Application |
|
 By Product |
|
 By End User |
|
 By Region |
|
 Key Market Players | Exiqon A/S, Sistemic Ltd, NX Pharmagen, Inc., Exosome Diagnostic, Inc., Aethlon Medical, Inc., NanoSomix, Inc, System Biosciences, Inc, Capricor Therapeutics, Inc., Thermo Fisher Scientific, Inc., Malvern Instruments Ltd |
Analyst Review
This section provides various opinions of the top-level CXOs in the clinical area of exosome-based research examination and studies. In accordance to several interviews conducted, utilization of exosome isolation instrument is expected to witness a significant rise with increase in focus on life science research, rise in diagnostic procedures for cancer, and surge in innovative and advanced applications of isolation kits.
Moreover, remarkable technological advancements in the exosome isolation kits and reagents to provide advanced extraction procedures from the body fluids surge the demand for molecular diagnosis drive the growth of the market. According to the CXOs of leading companies operating in this market, increase in prevalence of cancer, surge in technological advancements, and rise in emphasis on early diagnosis of cancer are some of the major factors driving market growth.
However, lack of awareness regarding the use of exosome therapeutics and stringent regulations for the approval of products used in exosome-based research hamper the growth of the market. Presently, the diagnostic application is the largest segment in the global exosome diagnostic and therapeutic market. According to the CXOs, rise in incidences of cancer, growth in geriatric population, and surge in initiatives by various government associations for screening of cancer boost the growth of the exosome diagnostic and therapeutic market.
According to the CXO’s, cancer institutes are the major end users in the exosome diagnostic and therapeutic market. This is due to the increase in focus of cancer prevention & treatment and rise in government supports in the form of funding to the cancer institutes. As per CXOs, North America is expected to dominate the global exosome diagnostic and therapeutic market during the forecast period, followed by Europe.
The total market value of exosome diagnostic and therapeutic market is $224.3 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of exosome diagnostic and therapeutic Market in 2021 was $288.3 million
The base year for the report is 2020.
Yes, exosome diagnostic and therapeutic companies are profiled in the report
The top companies that hold the market share in exosome diagnostic and therapeutic market are Aethlon Medical, Inc, Exosome Diagnostics Inc., NanoSomix Inc., Thermo Fisher Scientific Inc., Malvern Instruments Ltd., System Biosciences Inc, NX Pharmagen, Sistemic Inc., Capricor Therapeutics, and Exiqon A/S.
The key trends in the exosome diagnostic and therapeutic market are increase in prevalence of chronic disease, infectious disease, autoimmune disease and cancer and surge in demand for molecular diagnosis.
Loading Table Of Content...
Loading Research Methodology...
